MDB Capital Holdings, LLC reports developments as a public venture platform and investment holding company focused on launching and supporting disruptive technology companies. Its news commonly covers shareholder updates, operating results, portfolio-company positions, capital-market services and the activity of subsidiaries that combine broker-dealer, intellectual property and technology-development functions.
Company updates also feature PatentVest, MDB’s intellectual property intelligence, strategy and legal-services business. Recurring PatentVest releases discuss IP landscape reports, patent strategy, legal insights, biotechnology and medical-technology collaborations, and equity-linked service engagements that connect patent research, due diligence and venture formation.
MDB Capital Holdings (NASDAQ: MDBH), a public venture platform specializing in deep technology companies, has scheduled a Zoom webinar to discuss its Q4 and full year 2024 financial results on Monday, March 31, 2025, at 4:30 p.m. Eastern Time.
The earnings conference call will be led by CEO and Co-Founder Christopher Marlett, along with other management team members. They will review recent developments, ongoing initiatives, and anticipated milestones, followed by a Q&A session. The company will release detailed financial results before the call.
Investors can access the webinar through pre-registration or via MDB's investor relations website at https://investors.mdb.com/.
PatentVest has released a new Pulse Report analyzing the AI data center patent landscape, revealing China's dominance with 77% of global patent filings. The report highlights that five of the top patent holders are Chinese companies.
The data center as a service market, valued at $71.92 billion in 2022, is projected to reach $431.43 billion by 2030. This growth is driven by increasing demand for AI-optimized infrastructure and energy-efficient computing innovations.
Key market factors include:
- Technology innovations in AI-specific chip architectures and cooling systems
- Surge in patent filings for foundational technologies
- Significant patent litigation cases, including Intel's $2.18 billion ruling and Netlist's $118 million lawsuit against Samsung
Enterprise data generation is expected to reach 1.2 million exabytes by 2025, driving the need for advanced AI infrastructure solutions focusing on high-performance computing and real-time data processing.
eXoZymes (Nasdaq: EXOZ), a company specializing in AI-engineered enzymes for transforming sustainable feedstock into chemicals, medicines, and biofuels, announced that CEO Michael Heltzen and team members will ring the Nasdaq closing bell on February 19, 2025. This ceremony commemorates their successful IPO, which closed on November 14, 2024, with shares priced at $8 per share.
The bell ringing ceremony will be broadcast live at 3:50 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York City. The company views this milestone as a marker of transition into what they call the 'exozymes era of biotechnology,' following the synthetic biology era.
Invizyne Technologies announced its corporate rebranding to eXoZymes Inc, with its stock trading symbol changing from IZTC to EXOZ on the Nasdaq Capital Market. The company introduces 'exozymes' as a new scientific concept, positioning it as the successor to synthetic biology (SynBio), particularly focusing on industrial-scale production.
eXoZymes specializes in AI-engineered enzymes designed to operate outside living cells in bioreactors, transforming feedstocks into valuable chemicals, medicines, and biofuels. The company emphasizes this technology's potential to replace traditional chemical production methods with sustainable alternatives. The development process, powered by AI and enzymes, significantly reduces production timelines, with the company expecting to announce a new chemical development completed in just weeks.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced its corporate name change to eXoZymes, Inc. The company, currently trading under NASDAQ ticker IZTC, will change its ticker symbol to EXOZ, expected to take effect on February 12, 2025, pending final approvals.
The company will update its branding, including the corporate website, to reflect the new name. Existing shareholders are not required to take any action regarding the name and ticker symbol change. The CUSIP number for the company's common stock will remain unchanged.
PatentVest has released a comprehensive report on the Continuous Glucose Monitoring (CGM) market, highlighting significant growth prospects and technological innovations in diabetes care. The report reveals that the global CGM market, valued at $11.63 billion in 2024, is projected to reach $21 billion by 2029.
The analysis addresses the critical need for continuous glucose monitoring solutions, noting that diabetes affects 537 million adults worldwide, with projections reaching 783 million by 2045. Key market drivers include technological advancements in non-invasive monitoring, integration with mobile applications, and the emergence of over-the-counter (OTC) CGM products.
The report emphasizes the competitive landscape dominated by major players like Dexcom, Abbott, Medtronic, and Roche, highlighting their role in transforming diabetes management through innovation and strategic market positioning. A surge in patent filings and ongoing litigation trends underscore the market's competitive nature.
MDB Capital Holdings (NASDAQ: MDBH) provided its Q3 2024 operational update, highlighting significant achievements including the successful IPO of Invizyne Technologies where MDB retains 48% ownership. The company launched a collaboration with Mayo Clinic for an anti-senescence platform with 67% founding ownership. MDB enhanced its analysis capabilities, screening 8,751 companies and examining 217 potential market leaders. The company expanded its investor base by 15%, increased brokerage accounts by 450+, and grew assets under management from $2M to $28M. PatentVest client engagements increased from three to eight since 2023.
Invizyne Technologies (NASDAQ: IZTC) has been awarded a $2 million project from the U.S. Department of Defense's BioMADE initiative to advance sustainable aviation fuel (SAF) capabilities. The project, in partnership with the University of Georgia, focuses on enabling enzyme production for cell-free biomanufacturing of isobutanol, a key SAF precursor. This follows previous grants totaling $5.85 million from the Department of Energy. The project aims to develop an enzyme production pipeline and deploy technology in 100L pilot-scale facilities. The global SAF market is projected to grow at 52.2% annually, reaching $27.4 billion by 2032.
MDB Capital Holdings (NASDAQ: MDBH) has scheduled a Zoom webinar for Thursday, November 21, 2024, at 4:30 p.m. Eastern Time to discuss its third quarter 2024 results. CEO Christopher Marlett will lead the presentation, accompanied by management team members, to review recent developments, ongoing initiatives, and anticipated milestones. The company will release detailed financial results before the call. Investors can pre-register for the webinar through a provided link or access it via MDB's investor relations website.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced the closing of its Initial Public Offering of 1,875,000 common stock shares at $8.00 per share. Trading began on NASDAQ under symbol IZTC on November 13, 2024. The IPO raised approximately $15 million in gross proceeds. The company granted a 45-day option to the underwriter to purchase up to 281,250 additional shares. Additionally, in a concurrent private placement, Invizyne issued 93,750 warrants at $0.125 each, exercisable at $8.00 per share for five years.